Jojenelle R.

Tepait

BSN-2D

DRUG STUDY ABOUT PREGABALIN

I. GENERIC NAME:

 Pregabalin

II. BRAND NAME:

 Lyrica
 Lyrica R.

III. DRUG CLASSIFICATION

 Anticonvulsant

IV. THERAPEUTIC ACTION

 Pregabalin, marketed as Lyrica, alleviates conditions such as seizures, nerve pain (e.g.,
diabetic neuropathy), and anxiety. By calming overactive nerve signals in the central
nervous system, it helps control seizures, relieves nerve pain, and exhibits anxiolytic
effects. This is achieved through modulation of neurotransmitter release. Always seek
guidance from a healthcare professional for personalized advice on pregabalin use.

V. INDICATION

 Seizures; helps control seizures in adults and kids.

 Nerve pain; easies pain from conditions like diabetes, shingles, and spinal cord injuries
 Fibromyalgia; treats pain and discomfort relatedto fibromyalgia
 Anxiety; approved to help with general anxiety disorder.
 Spinal cord injury; relieves pain from injures to the spinal cord.
 Epilepsy; helps control seizures in adults with epilepsy.

VI. CONTRAINDICATION AND CAUTIONS

CONTRAINDICATIONS:

 Contraindicated in patients hypersensitive to drug or its components.

 Use with caution or avoid in individuals with a history of heart problems.
 Pregabalin is primarily exreted by ht ekidneys, so caution is advised in patients with
impaired kidney function.
 Individuals with a history of substance abuse dependence may need careful
consideration before using pregabalin.
 Suicidal thoughts
  Pregnancy and breastfeeding

CAUTIONS:

 Pregabalin may cause drowsiness or dizziness. Caution is advised when driving or

operating machinery
 Some individuals may experience fluid retention.
 Withdrawal Symptoms.
 Mood changes; anxiety and agitation
 Central Nervous system depression
 Pregnancy and breastfeeding

VII. AVAILABLE FORMS

 Capsule
 Solution
 Extended-release tablet

VIII. DOSAGES

 Diabetic Nerve Pain (Oral - Capsules and Solution):

 Adults: Start with 50 mg three times a day, not exceeding 300 mg per day.
 Children: Dosage determined by the doctor.
 Diabetic Nerve Pain (Extended-Release Tablets):
 Adults: Begin with 165 mg once daily, not exceeding 330 mg per day.
 Children: Dosage determined by the doctor.
 Partial-Onset Seizures (Oral - Capsules and Solution):
 Adults and Children (17 years and older): Initiate with 150 mg per day, up to 600 mg per
day.
 Children (1 month and older, based on weight): Dosage determined by the doctor.
 Fibromyalgia (Oral - Capsules and Solution):
 Adults: Start with 75 mg twice daily, not exceeding 450 mg per day.
 Children: Dosage determined by the doctor.
 Postherpetic Neuralgia (Oral - Capsules and Solution):
 Adults: Initiate with 75-150 mg twice daily or 50-100 mg three times a day, not exceeding
600 mg per day.
 Children: Dosage determined by the doctor.
 Postherpetic Neuralgia (Extended-Release Tablets):
 Adults: Begin with 165 mg once daily, not exceeding 660 mg per day.
 Children: Dosage determined by the doctor.
 Spinal Cord Injury Nerve Pain (Oral - Capsules and Solution):
 Adults: Start with 75 mg twice daily, not exceeding 600 mg per day.
 Children: Dosage determined by the doctor.

 IX. PHARMACOKINETICS

 Absorption: Pregabalin is rapidly absorbed after oral administration, with maximum

concentrations reached within 1 to 3 hours.
 Distribution: The drug has a low binding to plasma proteins, indicating a high degree of
distribution throughout the body. It crosses the blood-brain barrier, reaching the central nervous
system, where it exerts its effects.
 Metabolism: Pregabalin undergoes negligible metabolism in the liver. It is primarily eliminated
unchanged in the urine.
 Elimination: The elimination half-life of pregabalin is approximately 6.3 hours. Renal clearance
is the primary route of elimination, and approximately 90% of the administered dose is excreted
unchanged in the urine.

X. ADVERSE EFFECTS

 Dizziness
 Drowsiness
 Weight gain
 Peripheral edema
 Blurred vision
 Dry mouth
 Fatigue
 Headache
 Nausea
 Constipation
 Increased appetitie
 Muscle Pain/Weakness
 Difficulty concentrating
 Mood changes
 Suicidal thoughts.

XI. DRUG INTERACTION

 Alcohol: May increase dizziness and drowsiness.

 Opioids (e.g., morphine, oxycodone): Increased risk of drowsiness and respiratory
depression.
 Benzodiazepines (e.g., lorazepam, diazepam): Combined use can enhance sedation
and dizziness.
 Certain Antidepressants (e.g., duloxetine): May increase the risk of side effects such
as dizziness and drowsiness.
 Certain Antihypertensive Drugs: Pregabalin can sometimes cause fluid retention, and
combining it with certain blood pressure medications may increase this risk.
 NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): Increased risk of kidney problems
nwhen used with pregabali n.

XII. NURSING CONSIDERATIONS AND NURSING INTERVENTIONS

NURSING CONSIDERATIONS:

1. Thorough patient history and allergy assessment.

2. Inform about medication purpose, effects, and proper administration

3. Regularly assess effectiveness in pain/seizure management

4. Advise caution regarding dizziness.

5. Collaborate with the healthcare team to monitor and manage potential drug interactions.

NURSING INTERVENTIONS

1. Administer pregabalin at prescribed dosage and schedule.

2. Assist in managing common side effects like dizziness or drowsiness.

3. Encourage adequate fluid intake due to potential fluid retention.

4. Patient communication’ reporting unusual side effects.

5. Assess and discuss pregnancy/lactation status with female patients.

XIII. REFERENCES

Pregabalin: MedlinePlus drug information. (n.d.). https://medlineplus.gov/druginfo/meds/a605045.html?

fbclid=IwAR2OKlAA9AwYIrAzHe0KZMP_XW5gvCUm34izwjeCncBR6aQP8hs6RB7NqjM

Pregabalin (Oral route). (2024, February 11). https://www.mayoclinic.org/drugs-supplements/pregabalin-oral-route/proper-

use/drg-20067411?fbclid=IwAR2hBvDUewarfKPugadTEAcLUaDceIGFTN9QyZ27kl2sx8avVXHlCLLwDW4

Cross, A. L. (2022b, November 14). Pregabalin. StatPearls - NCBI Bookshelf.

https://www.ncbi.nlm.nih.gov/books/NBK470341/?fbclid=IwAR3qft9QgOephe3dvxCATOLvRZYYqLOxABzrtkbAfPqWP00-

IVK9YJtOsxU